Page last updated: 2024-11-13

lmt-28

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

LMT-28: an interleukin-6 inhibitor that binds gp130; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID49846977
CHEMBL ID3765505
SCHEMBL ID22261830
MeSH IDM000609330

Synonyms (13)

Synonym
CHEMBL3765505 ,
bdbm50145193
lmt-28, >=98% (hplc)
lmt-28
1239600-18-0
HY-102084
CS-0022963
(4s)-3-[(2s,3s)-3-hydroxy-2-methyl-4-methylene-1-oxononyl]-4-(1-methylethyl)-2-oxazolidinone
(4s)-3-[(2s,3s)-3-hydroxy-2-methyl-4-methylidenenonanoyl]-4-propan-2-yl-1,3-oxazolidin-2-one
AT25013
MS-24540
SCHEMBL22261830
AKOS040741964
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Interleukin-6 receptor subunit betaHomo sapiens (human)IC50 (µMol)5.90005.90005.90005.9000AID1277882
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (23)

Processvia Protein(s)Taxonomy
positive regulation of platelet aggregationInterleukin-6 receptor subunit betaHomo sapiens (human)
positive regulation of acute inflammatory responseInterleukin-6 receptor subunit betaHomo sapiens (human)
positive regulation of adaptive immune responseInterleukin-6 receptor subunit betaHomo sapiens (human)
glycogen metabolic processInterleukin-6 receptor subunit betaHomo sapiens (human)
positive regulation of cell population proliferationInterleukin-6 receptor subunit betaHomo sapiens (human)
positive regulation of vascular endothelial growth factor productionInterleukin-6 receptor subunit betaHomo sapiens (human)
positive regulation of cardiac muscle hypertrophyInterleukin-6 receptor subunit betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterleukin-6 receptor subunit betaHomo sapiens (human)
response to cytokineInterleukin-6 receptor subunit betaHomo sapiens (human)
interleukin-11-mediated signaling pathwayInterleukin-6 receptor subunit betaHomo sapiens (human)
oncostatin-M-mediated signaling pathwayInterleukin-6 receptor subunit betaHomo sapiens (human)
positive regulation of T cell proliferationInterleukin-6 receptor subunit betaHomo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT proteinInterleukin-6 receptor subunit betaHomo sapiens (human)
negative regulation of apoptotic processInterleukin-6 receptor subunit betaHomo sapiens (human)
negative regulation of neuron apoptotic processInterleukin-6 receptor subunit betaHomo sapiens (human)
positive regulation of osteoblast differentiationInterleukin-6 receptor subunit betaHomo sapiens (human)
positive regulation of Notch signaling pathwayInterleukin-6 receptor subunit betaHomo sapiens (human)
positive regulation of astrocyte differentiationInterleukin-6 receptor subunit betaHomo sapiens (human)
leukemia inhibitory factor signaling pathwayInterleukin-6 receptor subunit betaHomo sapiens (human)
intestinal epithelial cell developmentInterleukin-6 receptor subunit betaHomo sapiens (human)
interleukin-6-mediated signaling pathwayInterleukin-6 receptor subunit betaHomo sapiens (human)
interleukin-27-mediated signaling pathwayInterleukin-6 receptor subunit betaHomo sapiens (human)
ciliary neurotrophic factor-mediated signaling pathwayInterleukin-6 receptor subunit betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (18)

Processvia Protein(s)Taxonomy
interleukin-6 receptor activityInterleukin-6 receptor subunit betaHomo sapiens (human)
leukemia inhibitory factor receptor activityInterleukin-6 receptor subunit betaHomo sapiens (human)
oncostatin-M receptor activityInterleukin-6 receptor subunit betaHomo sapiens (human)
interleukin-6 receptor bindingInterleukin-6 receptor subunit betaHomo sapiens (human)
growth factor bindingInterleukin-6 receptor subunit betaHomo sapiens (human)
interleukin-6 bindingInterleukin-6 receptor subunit betaHomo sapiens (human)
ciliary neurotrophic factor receptor activityInterleukin-6 receptor subunit betaHomo sapiens (human)
interleukin-11 receptor activityInterleukin-6 receptor subunit betaHomo sapiens (human)
ciliary neurotrophic factor receptor bindingInterleukin-6 receptor subunit betaHomo sapiens (human)
protein bindingInterleukin-6 receptor subunit betaHomo sapiens (human)
coreceptor activityInterleukin-6 receptor subunit betaHomo sapiens (human)
growth factor bindingInterleukin-6 receptor subunit betaHomo sapiens (human)
interleukin-11 bindingInterleukin-6 receptor subunit betaHomo sapiens (human)
protein tyrosine kinase activator activityInterleukin-6 receptor subunit betaHomo sapiens (human)
identical protein bindingInterleukin-6 receptor subunit betaHomo sapiens (human)
interleukin-27 receptor activityInterleukin-6 receptor subunit betaHomo sapiens (human)
scaffold protein bindingInterleukin-6 receptor subunit betaHomo sapiens (human)
cytokine receptor activityInterleukin-6 receptor subunit betaHomo sapiens (human)
cytokine bindingInterleukin-6 receptor subunit betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
plasma membraneInterleukin-6 receptor subunit betaHomo sapiens (human)
membrane raftInterleukin-6 receptor subunit betaHomo sapiens (human)
extracellular regionInterleukin-6 receptor subunit betaHomo sapiens (human)
plasma membraneInterleukin-6 receptor subunit betaHomo sapiens (human)
membraneInterleukin-6 receptor subunit betaHomo sapiens (human)
dendriteInterleukin-6 receptor subunit betaHomo sapiens (human)
neuronal cell bodyInterleukin-6 receptor subunit betaHomo sapiens (human)
extracellular exosomeInterleukin-6 receptor subunit betaHomo sapiens (human)
interleukin-6 receptor complexInterleukin-6 receptor subunit betaHomo sapiens (human)
oncostatin-M receptor complexInterleukin-6 receptor subunit betaHomo sapiens (human)
ciliary neurotrophic factor receptor complexInterleukin-6 receptor subunit betaHomo sapiens (human)
external side of plasma membraneInterleukin-6 receptor subunit betaHomo sapiens (human)
receptor complexInterleukin-6 receptor subunit betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID1277882Inhibition of gp130-IL6/IL-Ralpha interaction in human HepG2 cells assessed as inhibition of IL-6-induced STAT3 activation by luciferase reporter gene assay2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Structure-activity relationship study of a series of novel oxazolidinone derivatives as IL-6 signaling blockers.
AID1277880Binding affinity to gp130 C6A mutant (unknown origin) at 0.19 to 200 uM by surface plasmon resonance analysis2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Structure-activity relationship study of a series of novel oxazolidinone derivatives as IL-6 signaling blockers.
AID1277881Binding affinity to gp130 V93A mutant (unknown origin) at 0.19 to 200 uM by surface plasmon resonance analysis2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Structure-activity relationship study of a series of novel oxazolidinone derivatives as IL-6 signaling blockers.
AID1277883Cytotoxicity against human HepG2 cells2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Structure-activity relationship study of a series of novel oxazolidinone derivatives as IL-6 signaling blockers.
AID1277884Binding affinity to wild-type gp130 (unknown origin) at 0.19 to 200 uM by surface plasmon resonance analysis2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Structure-activity relationship study of a series of novel oxazolidinone derivatives as IL-6 signaling blockers.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (40.00)24.3611
2020's6 (60.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.61

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.61 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.71 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.61)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]